Next-generation COVID-19 vaccines: here come the proteins
- 29 January 2021
- journal article
- editorial
- Published by Elsevier BV in The Lancet
- Vol. 397 (10275), 643-645
- https://doi.org/10.1016/s0140-6736(21)00258-0
Abstract
No abstract availableThis publication has 10 references indexed in Scilit:
- Efficacy and Safety of the mRNA-1273 SARS-CoV-2 VaccineThe New England Journal of Medicine, 2021
- Safety and immunogenicity of S-Trimer (SCB-2019), a protein subunit vaccine candidate for COVID-19 in healthy adults: a phase 1, randomised, double-blind, placebo-controlled trialThe Lancet, 2021
- Safety and Efficacy of the BNT162b2 mRNA Covid-19 VaccineThe New England Journal of Medicine, 2020
- Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UKThe Lancet, 2020
- An mRNA Vaccine against SARS-CoV-2 — Preliminary ReportThe New England Journal of Medicine, 2020
- Performance characteristics of five immunoassays for SARS-CoV-2: a head-to-head benchmark comparisonThe Lancet Infectious Diseases, 2020
- Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adultsNature, 2020
- Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trialThe Lancet, 2020
- Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor bindingThe Lancet, 2020
- Improvement of Pharmacokinetic Profile of TRAIL via Trimer-Tag Enhances its Antitumor Activity in vivoScientific Reports, 2017